Answers are grounded in this paper and cite their sources.
ObesityWeek 2025 served as another demonstration of the exciting and rapidly developing landscape of obesity medicine. High-profile presentations showcased two new daily pills for weight loss, semaglutide and orforglipron. The former has since been approved by the United States Food and Drug Administration (FDA) and made available as of January 2026; the latter is likely to receive FDA approval in the first half of 2026. Phase 2 research was presented on eloralintide, a selective, amylin agonist formulated as a weekly injection that yields up to 20% weight loss.
No takes yet. Share an insight, caveat, or question.
Anthony J. Millard (2026) studied this question.